Curetis GmbH

Curetis GmbH

Curetis offers innovative diagnostic solutions for molecular microbiology, that allow for the rapid and comprehensive detection of pathogens and their resistances to antibiotics in a broad range of infectious disease indications.

Curetis’ goal is to become a leading provider of innovative diagnostic solutions for molecular microbiology.

Curetis’ Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and genetic antimicrobial resistance markers in a broad range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures.

Infections with increasingly resistant pathogens is one of the biggest threats to healthcare globally. Improved and faster diagnostics are key in overcoming this challenge. The rapid diagnostics solutions of Curetis facilitate improved patient outcomes, stringent antibiotic stewardship and health-economic benefits.

Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.

Curetis’ wholly owned subsidiary Ares Genetics GmbH develops next-generation solutions for infectious disease diagnostics and the data-driven development of antibiotics. The ARES Technology Platform combines the presumably most comprehensive database worldwide on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence.

Category

Medical technology

Activity Biotechnology, Diagnostic, Research, Medical Products, Microorganisms

Management

Oliver Schacht, Ph.D. (CEO Curetis Group)
Dr. Achim Plum: (CBO Curetis Group & Managing Director Ares Genetics GmbH)
Johannes Bacher: COO Curetis Group & Co-Founder

Year of foundation

2007

Employees

90

Supervisory board

William E. Rhodes III (Chairman of the Board)
Dr. Werner Schäfer (Vice-Chairman)
Mario Crovetto
Dr. Prabhavathi Fernandes
Dr. Rudy Dekeyser
Dr. med. Nils Clausnitzer

Academic board

Europe:
Dr. Reno Frei (Basel, Switzerland)
Prof. Dr. Laurent Poirel (Fribourg, Switzerland)
Prof. Dr. Dr. Jean-Lois Vincent (Brussels, Belgium)

USA:
Debra Goff, Pharm.D. (The Ohio State University Wexner Medical Center, OH, USA)
Donna Mildvan, M.D. (Icahn School of Medicine at Mount Sinai, NY, USA)
Melissa Miller, Ph.D. (University of North Carolina at Chapel Hill School of Medicine, NC, USA)
Frederick Nolte, Ph.D. (Medical University of South Carolina, SC, USA)
Robin Patel, M.D. (Mayo Clinic, MN, USA)

Funding

Publicly listed on EURONEXT in Amsterdam and Brussels (Ticker: CURE)

Certificates

ISO 13485:2016

News

04.07.2019

Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing

Patent broadly covers genetic biomarkers and biomarker combinations indicating antibiotic resistance, First of eleven similar patents filed covering various pathogen/drug…

23.05.2019

Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples

Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced key data from its…

21.05.2019

Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville

Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that…

17.05.2019

Curetis Announces Financial Results for the First Three Months of 2019

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today reported its financial results for…